Compounds > deferasirox
Page last updated: 2024-09-05

deferasirox and Transfusion Reaction

deferasirox has been researched along with Transfusion Reaction in 115 studies

Research

Studies (115)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's22 (19.13)29.6817
2010's90 (78.26)24.3611
2020's3 (2.61)2.80

Authors

AuthorsStudies
Angelucci, E; Dong, X; Garcia-Manero, G; Ghosh, J; Greenberg, P; Hou, M; Izquierdo, M; Li, J; Montano Figueroa, EH; Rodriguez, MG; Wu, D1
Georgiev, PG; Goranov, SE; Goranova-Marinova, VS; Sapunarova, KG1
Blum, S; Dewarrat, N1
Gattermann, N1
Komrokji, RS; Shammo, JM1
Argenziano, M; Casale, M; Perrotta, S; Punzo, F; Rossi, F; Tortora, C1
Azmon, A; Beneitez Pastor, D; Bruederle, A; El-Beshlawy, A; Elalfy, M; Gilotti, G; Inusa, B; Soledada Duran Nieto, M; Xicoy, B1
Gallie, BL; Olivieri, NF; Sabouhanian, A1
Alimena, G; Breccia, M1
Cid, J; Díaz, M; Palomera, L; Solano, F; Zamora, C1
Chang, HH; Chung, KP; Ho, WL; Jou, ST; Lin, DT; Lin, KH; Lu, MY; Yang, SS; Yang, YL1
Pongtanakul, B; Viprakasit, V1
Butler, J; Curley, C; Durrant, S; Kennedy, GA; Morris, KL; Subramonpillai, E1
Adamaki, M; Athanasiadou, A; Ktena, YP; Lambrou, G; Moschovi, M1
Ammirabile, M; Casale, M; Cinque, P; Costantini, S; Di Matola, T; Filosa, A; Prossomariti, L; Ricchi, P; Spasiano, A1
Alvarez, O; Aygun, B; Bonner, M; Flanagan, J; Lockhart, A; Miller, ST; Mueller, BU; Owen, W; Schultz, W; Scott, JP; Ware, RE; Yovetich, NA1
Akyol, G; Baldane, S; Cetin, M; Eser, B; Kaynar, L; Keklik, M; Kurnaz, F; Pala, C; Sivgin, S; Unal, A; Zararsiz, G1
Belohlavkova, P; Cermak, J; Cervinek, L; Jonasova, A; Neuwirtova, R; Vondrakova, J1
Barrette, S; Files, B; Habr, D; Minniti, CP; Torres, M; Vichinsky, E; Zhang, Y1
Brunskill, SJ; Chowdhury, O; Doree, C; Fisher, SA; Gooding, S; Roberts, DJ1
Bina, P; Cossa, S; Danjou, F; Defraia, E; Dessì, C; Foschini, ML; Galanello, R; Leoni, G; Matta, G; Morittu, M; Origa, R1
Cappellini, MD; Taher, AT; Temraz, S1
de Witte, T1
Chung, J; Jang, JH; Jo, DY; Kim, HJ; Lee, JH; Lee, JW; Yoon, SS1
Abe, T; Fujii, S; Fujita, M; Iyama, S; Jomen, W; Kato, J; Kobune, M; Kuroda, H; Maeda, M; Matsuno, T; Miyanishi, K; Nagashima, K; Sakurai, T; Sato, M; Yamada, M1
Cheong, JW; Chung, J; Hyun, MS; Jo, DY; Joo, YD; Jung, CW; Kim, BS; Kim, CS; Kim, HJ; Kim, HY; Lee, JH; Lee, KH; Min, YH; Park, CY; Park, HS; Seong, CM; Shim, H; Sohn, SK; Yoon, HJ; Yoon, SS1
Abdollah Gorji, F; Alavi, S; Arzanian, MT; Ebadi, M; Ghazizadeh, F; Shamsian, B1
Cappellini, MD; Chuncharunee, S; Habr, D; Karakas, Z; Kattamis, A; Origa, R; Porter, JB; Siritanaratkul, N; Sutcharitchan, P; Taher, AT; Viprakasit, V; Zhu, Z1
Alimena, G; Angelucci, E; Borin, L; Caocci, G; Cilloni, D; Di Tucci, AA; Fazi, P; Fenu, S; Finelli, C; Latte, G; Molteni, A; Piciocchi, A; Quaresmini, G; Quarta, G; Rivellini, F; Salvi, F; Sanpaolo, G; Santini, V; Storti, S; Tura, S; Vallisa, D; Vignetti, M; Volpe, A; Voso, MT1
Clissa, C; Finelli, C; Stanzani, M1
Alam, MH; Carpenter, JP; Garbowski, MW; He, T; Pennell, DJ; Porter, JB; Roughton, M; Smith, G1
Cappellini, MD; Castiglioni, C; Longo, F; Origa, R; Piga, A; Pinna, F; Roggero, S; Zappu, A1
Hikota, R; Horiuchi, T; Kato, S; Kimura, F; Kobayashi, A; Kobayashi, S; Maekawa, T; Osawa, Y; Sato, K; Watanabe, J; Yamamura, T1
Chan, GC; Cheuk, DK; Chiang, AK; Dee, CM; Ha, SY1
Batlle, M; Belloch, V; Duarte, R; Hernández, D; Jarque, I; Jiménez, M; Jiménez, S; López, J; Rovira, M; Sampol, A; Solano, C; Valcárcel, D; Vallejo, C; Vázquez, L1
Díaz-García, JD; Gallegos-Villalobos, A; Gonzalez-Espinoza, L; Ortiz, A; Sanchez-Niño, MD; Villarrubia, J1
Atipas, S; Kusuwan, T; Limviriyakul, S; Pooliam, J; Sangpraypan, T; Tanphaichitr, A; Tanphaichitr, VS; Viprakasit, V1
Gadong, N; Hemmaway, C; Kaya, B; Newell, H; Simmons, A; Telfer, P; Tsouana, E; Whitmarsh, S1
Chen, CH; Shu, KH; Yang, Y1
Alimena, G; Angelucci, E; Borin, L; Cilloni, D; Cottone, F; Di Tucci, AA; Efficace, F; Fenu, S; Finelli, C; La Nasa, G; Mandelli, F; Molteni, A; Quaresmini, G; Quarta, G; Rivellini, F; Salvi, F; Sanpaolo, G; Santini, V; Volpe, A; Voso, MT1
Aydinok, Y; El-Beshlawy, A; Elalfy, M; Habr, D; Kilinç, Y; Lai, YR; Musallam, KM; Pennell, DJ; Piga, A; Porter, JB; Shen, J; Yesilipek, A1
Bouillaud, E; Cappellini, MD; Forni, GL; Fracchia, S; Habr, D; Hirschberg, R; Lai, ME; Piga, A; Wegener, A1
Aloe Spiriti, MA; Breccia, M; Buccisano, F; Criscuolo, M; D'Addosio, A; Fenu, S; Fragasso, A; Latagliata, R; Maurillo, L; Musto, P; Niscola, P; Piccioni, AL; Refrigeri, M; Tatarelli, C; Trapè, G; Venditti, A; Voso, MT1
Attri, SV; Bansal, D; Bhatia, P; Marwaha, RK; Totadri, S; Trehan, A1
Aydinok, Y; Cappellini, MD; Constantinovici, N; El-Beshlawy, A; Elalfy, M; Habr, D; Karakas, Z; Kattamis, A; Kilinç, Y; Origa, R; Perrotta, S; Porter, JB; Shen, J; Viprakasit, V1
Erman, A; Feige Gross Nevo, R; Gafter, U; Gafter-Gvili, A; Milo, G; Pazgal, I; Shpilberg, O; Stark, P1
Cohen, AR; Davis, BR; Heeney, MM; Kwiatkowski, JL; Lee, MT; Odame, I; Owen, WC; Pressel, S; Rogers, ZR; Schultz, WH; St Pierre, T; Ware, RE; Wood, JC1
Alimena, G; Andriani, A; Bagnato, A; Breccia, M; Cedrone, M; Ciccone, F; De Muro, M; Di Veroli, A; Latagliata, R; Leonetti, SC; Maurillo, L; Montagna, C; Montanaro, M; Montefusco, E; Niscola, P; Porrini, R; Rago, A; Spadea, A; Spirito, F1
Angelucci, E; Breccia, M; Gattermann, N; Hofmann, WK; Nolte, F; Santini, V; Vey, N1
D'Ascola, DG; Fragomeno, C; Roccabruna, E1
Escudero-Vilaplana, V; Garcia-Gonzalez, X; Osorio-Prendes, S; Romero-Jimenez, RM; Sanjurjo-Saez, M1
Corpino, M; Dessì, C; Foschini, ML; Leoni, G; Moi, P; Morittu, M; Origa, R; Zappu, A1
Daniele, C; Equitani, F; Guitarrini, MR; Losardo, A; Maffei, L; Monti, S; Pasin, M; Poggi, M; Pugliese, P; Smacchia, MP; Sorrentino, F; Terlizzi, F; Toscano, V1
Gomber, S; Jain, P; Narang, M; Sharma, S1
Arora, S; Athale, UH; Bhatt, MD; Kirby-Allen, M; Papneja, K; Wiernikowski, JT1
Bruch, HR; Dencausse, Y; Heßling, J; Michl, G; Schlag, R; Schneider-Schranz, C; Schulte, C; Skorupa, A; Tesch, H; Wolf, S1
Badcock, CA; Bowden, DK; Brown, G; Gervasio, OL; Grigg, A; Ho, PJ; Marlton, P; St Pierre, T; Tay, L; Teo, J; Traficante, R1
Avazpour, A; Badie, A; Haghpanah, S; Karimi, M; Toosi, F1
Arboscello, E; Biale, L; Del Corso, L; Filiberti, R; Parodi, EL; Russo, R1
Aydinok, Y; El-Ali, A; El-Beshlawy, A; Elalfy, M; Han, J; Lee, SH; Porter, JB; Sutcharitchan, P; Taher, A1
Al Zoebie, A; Bruederle, A; Chotsampancharoen, T; El-Beshlawy, A; Elalfy, M; Gilotti, G; Han, J; Kamdem, A; Koussa, S; Vichinsky, E1
Brewster, UC; McPhedran, P; Yusuf, B1
Cappellini, MD; Taher, A1
Dinter, D; Dorn-Beineke, A; Hastka, J; Hehlmann, R; Leismann, O; Lutz, K; Metzgeroth, G; Schultheis, B1
Kontoghiorghes, GJ3
Bagust, A; Boland, A; Chu, P; Dickson, R; Dundar, Y; Fleeman, N; Greenhalgh, J; Kirkham, J; McLeod, C; Modell, B; Olujohungbe, A; Telfer, P; Walley, T1
Stone, RM; Tefferi, A1
Bergmann, AK; Braunstein, J; Chirnomas, D; Finkelstein, Y; Grant, FD; Neufeld, EJ; Paley, C; Pereira, L; Shannon, M; Smith, AL1
Cappellini, MD; Clark, J; Galanello, R; Habr, D; Lawniczek, T; Piga, A; Porter, JB; Taher, A; Vichinsky, E1
Porter, JB1
Becker-Cohen, R; Even-Or, E; Miskin, H1
Bruin, GJ; Glaenzel, U; Hazell, K; Porter, JB; Sechaud, R; Waldmeier, F; Warrington, S1
Fujita, T; Haba, R; Nishiuchi, T; Ohnishi, H; Okutani, Y; Yoshida, K1
Balocco, M; Carrara, P; Forni, GL; Pinto, V1
Berdoukas, V; Berdoussi, E; Chouliaras, G; Kattamis, C; Ladis, V; Moraitis, P; Zannikos, K1
Hershko, C1
Coates, TD; Giardina, P; Glynos, T; Harmatz, P; Kang, BP; Paley, C; Thompson, A; Wood, JC1
Im, HJ; Kim, BE; Koh, KN; Park, M; Seo, JJ1
Chang, HH; Chang, TT; Chiou, SS; Jou, ST; Liao, YM; Lin, DT; Lin, KH; Lin, PC; Lu, MY; Yang, YL1
Cheng, CH; Lo, FS; Wei, HY; Yang, CP1
Bianchino, G; Bochicchio, GB; D'Auria, F; Grieco, V; Guariglia, R; Lerose, R; Mansueto, G; Martorelli, MC; Musto, P; Pietrantuono, G; Villani, O1
Chandra, J; Chaudhary, H; Dutta, AK; Pemde, H; Singh, V1
Bernaudin, F; Coates, T; Deng, W; Forni, GL; Gardner, R; Giannone, V; Griffel, L; Hassell, K; Heeney, MM; Inusa, B; Kutlar, A; Lane, P; Mathias, L; Porter, J; Tebbi, C; Vichinsky, E; Wilson, F1
Chen, GF; Chen, JJ; Gao, HY; Li, CG; Li, Q1
Musallam, KM; Taher, AT1
Blumenstengel, K; Gattermann, N; Germing, U; Goebeler, M; Groschek, M; Jarisch, A; Junkes, A; Leismann, O; Losem, C; Procaccianti, M; Schlag, R1
Alvarez, O; Cohen, AR; Garro, J; Kwiatkowski, JL; Lane, P; Mortier, N; Mueller, B; Nagasubramanian, R; Sarnaik, S; Schultz, W; Thompson, A; Ware, RE; Woods, GM; Yovetich, N1
Campus, S; Galanello, R; Origa, R1
Fernandes, JL1
Della Porta, M; Fenaux, P; Finelli, C; Gattermann, N; Guerci-Bresler, A; Habr, D; Marcellari, A; Rose, C; Roubert, B; Schmid, M; Stadler, M; Taylor, K; Vassilieff, D1
Bae, SJ; Chueh, HW; Kang, C; Koo, HH; Lee, SH; Son, MH; Sung, KW; Yoo, KH1
Cochat, P; Dubourg, L; Hadj-Aïssa, A; Laurain, C; Pondarré, C; Ranchin, B; Sigaudo-Roussel, D1
Araki, H; Hara, T; Moriwaki, H; Oyama, M; Tsurumi, H; Yoshikawa, T1
Arnold, L; Kurtin, SE; Lindroos-Kolqvist, P; Shah, J; Tinsley, S1
Cappellini, MD; Hoffbrand, AV; Taher, A1
Agapidou, A; Economou, M; Efthimia, V; Neokleous, N; Perifanis, V; Teli, A; Vetsiou, E1
Baier, M; Gattermann, N; Giagounidis, A; Haase, D; Höchsmann, B; Hofmann, WK; Junkes, A; Leismann, O; Lübbert, M; Lück, A; Nolte, F; Platzbecker, U; Schrezenmeier, H; Schumann, C; Taupitz, M1
Aydinok, Y; Chan, LL; El-Beshlawy, A; Elalfy, MS; Habr, D; Lee, SH; Martin, N; Porter, JB; Sutcharitchan, P; Taher, AT1
Maekawa, T; Yoshioka, S1
Cho, BS; Cho, SG; Eom, KS; Kim, DW; Kim, HJ; Kim, YJ; Lee, JW; Lee, S; Lee, SE; Min, CK; Min, WS; Park, CW; Yahng, SA1
Azarkeivan, A; Bordbar, MR; Cohan, N; Haghpanah, S; Karimi, M; Zareifar, S1
Javanbakht, M; Karimi, M; Keshtkaran, A; Mashayekhi, A; Nuri, B; Salavati, S1
Cabantchik, ZI; Hershko, C; Konijn, AM; Link, G1
Galanello, R1
Neufeld, EJ1
Alberti, D; Bordone, E; Cappellini, MD; Donato, G; Ford, JM; Forni, GL; Galanello, R; Hewson, N; Lavagetto, A; Opitz, H; Origa, R; Piga, A; Sechaud, R; Zanaboni, L; Zappu, A1
Stumpf, JL1
Keam, SJ; Keating, GM; Yang, LP1
Goldberg, SL1
Vichinsky, E1
Abetz, L; Baladi, JF; Coates, T; Coïc, L; Files, B; Fischer, R; Forni, GL; Lane, P; Marks, P; Mueller, BU; Onyekwere, O; Pakbaz, Z; Porter, J; Rofail, D; Swerdlow, P; Vichinsky, E1
Breuer, W; Cabantchik, ZI; Hershko, C; Konijn, AM; Link, G; Nick, HP1

Reviews

24 review(s) available for deferasirox and Transfusion Reaction

ArticleYear
Iron overload in myelodysplastic syndromes (MDS).
    International journal of hematology, 2018, Volume: 107, Issue:1

    Topics: Benzoates; Blood Transfusion; Deferasirox; Deferoxamine; Erythropoiesis; Hepcidins; Humans; Intestinal Mucosa; Iron; Iron Chelating Agents; Iron Overload; Liver; Myelodysplastic Syndromes; Transfusion Reaction; Triazoles

2018
Clinical consequences of iron overload in patients with myelodysplastic syndromes: the case for iron chelation therapy.
    Expert review of hematology, 2018, Volume: 11, Issue:7

    Topics: Blood Transfusion; Deferasirox; Disease-Free Survival; Humans; Iron Chelating Agents; Iron Overload; Myelodysplastic Syndromes; Randomized Controlled Trials as Topic; Survival Rate; Transfusion Reaction

2018
Efficacy and safety of deferasirox in myelodysplastic syndromes.
    Annals of hematology, 2013, Volume: 92, Issue:7

    Topics: Benzoates; Chelation Therapy; Clinical Trials, Phase II as Topic; Deferasirox; Drug Eruptions; Drug Therapy, Combination; Ferritins; Gastrointestinal Diseases; Humans; Iron; Iron Chelating Agents; Iron Overload; Kidney Diseases; Multicenter Studies as Topic; Myelodysplastic Syndromes; NF-kappa B; Oxidative Stress; Prospective Studies; Retrospective Studies; Survival Analysis; Transfusion Reaction; Triazoles

2013
Desferrioxamine mesylate for managing transfusional iron overload in people with transfusion-dependent thalassaemia.
    The Cochrane database of systematic reviews, 2013, Aug-21, Issue:8

    Topics: Benzoates; Chelation Therapy; Deferasirox; Deferiprone; Deferoxamine; Humans; Iron Chelating Agents; Iron Overload; Pyridones; Randomized Controlled Trials as Topic; Siderophores; Thalassemia; Transfusion Reaction; Triazoles

2013
Deferasirox for the treatment of iron overload in non-transfusion-dependent thalassemia.
    Expert review of hematology, 2013, Volume: 6, Issue:5

    Topics: Benzoates; Deferasirox; Humans; Iron Chelating Agents; Iron Overload; Thalassemia; Transfusion Reaction; Triazoles

2013
Deferasirox nephrotoxicity-the knowns and unknowns.
    Nature reviews. Nephrology, 2014, Volume: 10, Issue:10

    Topics: Acute Kidney Injury; Benzoates; Deferasirox; Glomerular Filtration Rate; Humans; Iron Chelating Agents; Iron Overload; Renal Insufficiency, Chronic; Transfusion Reaction; Triazoles

2014
Updated recommendations on the management of gastrointestinal disturbances during iron chelation therapy with Deferasirox in transfusion dependent patients with myelodysplastic syndrome - Emphasis on optimized dosing schedules and new formulations.
    Leukemia research, 2015, Volume: 39, Issue:10

    Topics: Benzoates; Chelation Therapy; Deferasirox; Gastrointestinal Diseases; Humans; Iron Chelating Agents; Myelodysplastic Syndromes; Transfusion Reaction; Triazoles

2015
Fanconi Syndrome Secondary to Deferasirox in Diamond-Blackfan Anemia: Case Series and Recommendations for Early Diagnosis.
    Pediatric blood & cancer, 2016, Volume: 63, Issue:8

    Topics: Adolescent; Adult; Aged; Anemia, Diamond-Blackfan; Benzoates; Blood Transfusion; Child; Deferasirox; Electrolytes; Fanconi Syndrome; Female; Humans; Iron Chelating Agents; Iron Overload; Male; Transfusion Reaction; Triazoles

2016
Long-term experience with deferasirox (ICL670), a once-daily oral iron chelator, in the treatment of transfusional iron overload.
    Expert opinion on pharmacotherapy, 2008, Volume: 9, Issue:13

    Topics: Administration, Oral; Benzoates; Clinical Trials as Topic; Deferasirox; Deferoxamine; Humans; Iron Chelating Agents; Iron Overload; Transfusion Reaction; Triazoles

2008
Deferasirox for the treatment of iron overload associated with regular blood transfusions (transfusional haemosiderosis) in patients suffering with chronic anaemia: a systematic review and economic evaluation.
    Health technology assessment (Winchester, England), 2009, Volume: 13, Issue:1

    Topics: Anemia; Benzoates; Chronic Disease; Contraindications; Cost-Benefit Analysis; Deferasirox; Deferiprone; Deferoxamine; Drug Therapy, Combination; Hemosiderosis; Humans; Iron Chelating Agents; Pyridones; Randomized Controlled Trials as Topic; Technology Assessment, Biomedical; Transfusion Reaction; Treatment Outcome; Triazoles

2009
Efficacy and safety of deferasirox doses of >30 mg/kg per d in patients with transfusion-dependent anaemia and iron overload.
    British journal of haematology, 2009, Volume: 147, Issue:5

    Topics: Adolescent; Adult; Anemia; Benzoates; Child; Child, Preschool; Creatinine; Deferasirox; Drug Administration Schedule; Female; Ferritins; Humans; Iron Chelating Agents; Iron Overload; Male; Middle Aged; Retrospective Studies; Transfusion Reaction; Treatment Outcome; Triazoles; Young Adult

2009
Deferasirox: an update.
    Hemoglobin, 2009, Volume: 33 Suppl 1

    Topics: Benzoates; Deferasirox; Humans; Iron; Iron Chelating Agents; Iron Overload; Myocardium; Transfusion Reaction; Treatment Outcome; Triazoles

2009
Positive effects on hematopoiesis in patients with myelodysplastic syndrome receiving deferasirox as oral iron chelation therapy: a brief review.
    Leukemia research, 2011, Volume: 35, Issue:5

    Topics: Administration, Oral; Aged; Benzoates; Chelation Therapy; Deferasirox; Hematopoiesis; Humans; Iron Chelating Agents; Male; Myelodysplastic Syndromes; Transfusion Reaction; Triazoles; Up-Regulation

2011
Iron chelation therapy for transfusional iron overload: a swift evolution.
    Hemoglobin, 2011, Volume: 35, Issue:5-6

    Topics: Benzoates; Chelation Therapy; Deferasirox; Deferiprone; Humans; Iron Chelating Agents; Iron Overload; Pyridones; Transfusion Reaction; Treatment Outcome; Triazoles

2011
Deferasirox: pharmacokinetics and clinical experience.
    Expert opinion on drug metabolism & toxicology, 2012, Volume: 8, Issue:1

    Topics: Animals; Benzoates; Clinical Trials as Topic; Deferasirox; Humans; Iron Chelating Agents; Iron Overload; Iron, Dietary; Transfusion Reaction; Triazoles

2012
Iron chelation therapy in the management of transfusion-related cardiac iron overload.
    Transfusion, 2012, Volume: 52, Issue:10

    Topics: Benzoates; Cardiomyopathy, Dilated; Chelation Therapy; Cross-Sectional Studies; Deferasirox; Deferiprone; Deferoxamine; Double-Blind Method; Drug Therapy, Combination; Forecasting; Humans; Iron Chelating Agents; Iron Overload; Magnetic Resonance Imaging; Practice Guidelines as Topic; Prospective Studies; Pyridones; Randomized Controlled Trials as Topic; Retrospective Studies; Transfusion Reaction; Treatment Outcome; Triazoles; Ventricular Dysfunction, Left

2012
Management of transfusion-related iron overload in patients with myelodysplastic syndromes.
    Clinical journal of oncology nursing, 2012, Volume: 16 Suppl

    Topics: Benzoates; Chelation Therapy; Deferasirox; Deferiprone; Deferoxamine; Humans; Iron; Iron Chelating Agents; Iron Overload; Myelodysplastic Syndromes; Phlebotomy; Pyridones; Siderophores; Transfusion Reaction; Triazoles

2012
Objectives and mechanism of iron chelation therapy.
    Annals of the New York Academy of Sciences, 2005, Volume: 1054

    Topics: Animals; Benzoates; Cardiomyopathies; Cells, Cultured; Chelation Therapy; Clinical Trials as Topic; Deferasirox; Deferiprone; Deferoxamine; Drug Administration Routes; Drug Synergism; Drug Therapy, Combination; Ferritins; Humans; Iron; Iron Chelating Agents; Iron Overload; Mitochondria, Heart; Mononuclear Phagocyte System; Pyridones; Rats; Thalassemia; Transfusion Reaction; Triazoles

2005
Oral chelators deferasirox and deferiprone for transfusional iron overload in thalassemia major: new data, new questions.
    Blood, 2006, May-01, Volume: 107, Issue:9

    Topics: Administration, Oral; Benzoates; beta-Thalassemia; Clinical Trials as Topic; Costs and Cost Analysis; Deferasirox; Deferiprone; Deferoxamine; Heart Diseases; Humans; Iron Chelating Agents; Iron Overload; Pyridones; Transfusion Reaction; Triazoles

2006
Future chelation monotherapy and combination therapy strategies in thalassemia and other conditions. comparison of deferiprone, deferoxamine, ICL670, GT56-252, L1NAll and starch deferoxamine polymers.
    Hemoglobin, 2006, Volume: 30, Issue:2

    Topics: Benzoates; Carboxylic Acids; Chelation Therapy; Clinical Trials as Topic; Deferasirox; Deferiprone; Deferoxamine; Drug Evaluation; Drug Therapy, Combination; Forecasting; Hemochromatosis; Humans; Hydroxyethyl Starch Derivatives; Iron Chelating Agents; Iron Overload; Molecular Structure; Pyridones; Starch; Thalassemia; Thiazoles; Transfusion Reaction; Triazoles

2006
Deferasirox.
    American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2007, Mar-15, Volume: 64, Issue:6

    Topics: Adult; Benzoates; Child; Deferasirox; Deferoxamine; Hematologic Diseases; Hemosiderosis; Humans; Iron; Iron Chelating Agents; Iron Overload; Patient Compliance; Siderophores; Transfusion Reaction; Triazoles

2007
Deferasirox : a review of its use in the management of transfusional chronic iron overload.
    Drugs, 2007, Volume: 67, Issue:15

    Topics: Animals; Benzoates; Blood Transfusion; Chronic Disease; Deferasirox; Humans; Iron; Iron Chelating Agents; Iron Overload; Liver; Transfusion Reaction; Triazoles

2007
Novel treatment options for transfusional iron overload in patients with myelodysplastic syndromes.
    Leukemia research, 2007, Volume: 31 Suppl 3

    Topics: Benzoates; Deferasirox; Deferiprone; Drug-Related Side Effects and Adverse Reactions; Humans; Iron Chelating Agents; Iron Overload; Myelodysplastic Syndromes; Pyridones; Survival Rate; Transfusion Reaction; Treatment Outcome; Triazoles

2007
Clinical application of deferasirox: practical patient management.
    American journal of hematology, 2008, Volume: 83, Issue:5

    Topics: Administration, Oral; Adult; Benzoates; Chemical and Drug Induced Liver Injury; Child; Clinical Trials as Topic; Contraindications; Creatinine; Deferasirox; Disease Management; Drug Eruptions; Gastrointestinal Diseases; Hematologic Diseases; Hemosiderosis; Humans; Iron; Iron Chelating Agents; Iron Overload; Kidney Diseases; Transfusion Reaction; Triazoles

2008

Trials

32 trial(s) available for deferasirox and Transfusion Reaction

ArticleYear
Iron Chelation in Transfusion-Dependent Patients With Low- to Intermediate-1-Risk Myelodysplastic Syndromes: A Randomized Trial.
    Annals of internal medicine, 2020, 04-21, Volume: 172, Issue:8

    Topics: Adult; Aged; Aged, 80 and over; Blood Transfusion; Cause of Death; Deferasirox; Double-Blind Method; Female; Ferritins; Humans; Iron Chelating Agents; Iron Overload; Male; Middle Aged; Myelodysplastic Syndromes; Patient Acuity; Progression-Free Survival; Transfusion Reaction; Young Adult

2020
International sentinel site surveillance of patients with transfusional hemosiderosis treated with deferasirox in actual practice setting.
    Hematology (Amsterdam, Netherlands), 2019, Volume: 24, Issue:1

    Topics: Adolescent; Adult; Aged; Blood Transfusion; Deferasirox; Female; Hemosiderosis; Humans; Iron Overload; Male; Middle Aged; Retrospective Studies; Transfusion Reaction

2019
A prospective phase II randomized study of deferasirox to prevent iatrogenic iron overload in patients undertaking induction/consolidation chemotherapy for acute myeloid leukaemia.
    British journal of haematology, 2013, Volume: 161, Issue:6

    Topics: Adult; Aged; Benzoates; Consolidation Chemotherapy; Deferasirox; Early Termination of Clinical Trials; Female; Ferritins; Humans; Iatrogenic Disease; Induction Chemotherapy; Iron Chelating Agents; Iron Overload; Leukemia, Myeloid, Acute; Male; Middle Aged; Recurrence; Transfusion Reaction; Treatment Outcome; Triazoles; Young Adult

2013
Iron chelation with deferasirox for the treatment of secondary hemosiderosis in pediatric oncology patients: a single-center experience.
    Journal of pediatric hematology/oncology, 2013, Volume: 35, Issue:6

    Topics: Adolescent; Benzoates; Chelation Therapy; Child; Child, Preschool; Deferasirox; Female; Ferritins; Hemosiderosis; Humans; Infant; Iron; Iron Chelating Agents; Male; Neoplasms; Transfusion Reaction; Triazoles; Young Adult

2013
Pain and other non-neurological adverse events in children with sickle cell anemia and previous stroke who received hydroxyurea and phlebotomy or chronic transfusions and chelation: results from the SWiTCH clinical trial.
    American journal of hematology, 2013, Volume: 88, Issue:11

    Topics: Acute Chest Syndrome; Adolescent; Adult; Anemia, Sickle Cell; Antisickling Agents; Benzoates; Chelation Therapy; Child; Child, Preschool; Cohort Studies; Deferasirox; Female; Humans; Hydroxyurea; Incidence; Iron Chelating Agents; Iron Overload; Male; Pain Measurement; Phlebotomy; Secondary Prevention; Stroke; Transfusion Reaction; Triazoles; Young Adult

2013
The oral iron chelator deferasirox might improve survival in allogeneic hematopoietic cell transplant (alloHSCT) recipients with transfusional iron overload.
    Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis, 2013, Volume: 49, Issue:2

    Topics: Adult; Allografts; Benzoates; Deferasirox; Disease-Free Survival; Female; Hematopoietic Stem Cell Transplantation; Humans; Iron Chelating Agents; Iron Overload; Male; Retrospective Studies; Survival Rate; Transfusion Reaction; Triazoles

2013
Efficacy and safety of deferasirox compared with deferoxamine in sickle cell disease: two-year results including pharmacokinetics and concomitant hydroxyurea.
    American journal of hematology, 2013, Volume: 88, Issue:12

    Topics: Acute Kidney Injury; Adolescent; Adult; Anemia, Sickle Cell; Benzoates; Cellulitis; Chelation Therapy; Chemical and Drug Induced Liver Injury; Child; Child, Preschool; Deferasirox; Deferoxamine; Drug Therapy, Combination; Female; Ferritins; Humans; Hydroxyurea; Iron Chelating Agents; Iron Overload; Male; Middle Aged; Prospective Studies; Transfusion Reaction; Triazoles; Young Adult

2013
Deferasirox improves hematologic and hepatic function with effective reduction of serum ferritin and liver iron concentration in transfusional iron overload patients with myelodysplastic syndrome or aplastic anemia.
    Transfusion, 2014, Volume: 54, Issue:6

    Topics: Adult; Aged; Anemia, Aplastic; Benzoates; Deferasirox; Female; Ferritins; Humans; Iron; Iron Overload; Liver; Male; Middle Aged; Myelodysplastic Syndromes; Prospective Studies; Transfusion Reaction; Triazoles

2014
Efficacy and safety of deferasirox in β-thalassemia major patients in Iran: a prospective study from a single referral center in Iran.
    Pediatric hematology and oncology, 2014, Volume: 31, Issue:1

    Topics: Adolescent; Adult; Benzoates; beta-Thalassemia; Chelation Therapy; Child; Child, Preschool; Deferasirox; Drug Eruptions; Female; Ferritins; Gastrointestinal Diseases; Humans; Iran; Iron; Iron Chelating Agents; Iron Overload; Liver; Magnetic Resonance Imaging; Male; Myocardium; Prospective Studies; Stroke Volume; Transfusion Reaction; Treatment Outcome; Triazoles; Young Adult

2014
Approaching low liver iron burden in chelated patients with non-transfusion-dependent thalassemia: the safety profile of deferasirox.
    European journal of haematology, 2014, Volume: 92, Issue:6

    Topics: Benzoates; Deferasirox; Humans; Iron; Iron Chelating Agents; Iron Overload; Liver; Thalassemia; Transfusion Reaction; Treatment Outcome; Triazoles

2014
Deferasirox for transfusion-dependent patients with myelodysplastic syndromes: safety, efficacy, and beyond (GIMEMA MDS0306 Trial).
    European journal of haematology, 2014, Volume: 92, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Benzoates; Blood Transfusion; Deferasirox; Female; Ferritins; Humans; Iron Chelating Agents; Iron Overload; Male; Middle Aged; Myelodysplastic Syndromes; Risk Factors; Transfusion Reaction; Treatment Outcome; Triazoles; Young Adult

2014
Deferasirox for cardiac siderosis in β-thalassaemia major: a multicentre, open label, prospective study.
    British journal of haematology, 2014, Volume: 167, Issue:3

    Topics: Adult; Benzoates; beta-Thalassemia; Cardiomyopathies; Chelation Therapy; Deferasirox; Female; Ferritins; Hemosiderosis; Humans; Iron Chelating Agents; Liver; Magnetic Resonance Imaging; Male; Medication Adherence; Prospective Studies; Stroke Volume; Transfusion Reaction; Triazoles; Young Adult

2014
Phase IV open-label study of the efficacy and safety of deferasirox after allogeneic stem cell transplantation.
    Haematologica, 2014, Volume: 99, Issue:10

    Topics: Adult; Aged; Benzoates; Deferasirox; Female; Ferritins; Hematopoietic Stem Cell Transplantation; Humans; Iron Chelating Agents; Iron Overload; Male; Middle Aged; Transfusion Reaction; Transplantation, Homologous; Treatment Outcome; Triazoles; Young Adult

2014
Sustained improvements in myocardial T2* over 2 years in severely iron-overloaded patients with beta thalassemia major treated with deferasirox or deferoxamine.
    American journal of hematology, 2015, Volume: 90, Issue:2

    Topics: Adolescent; Adult; Benzoates; beta-Thalassemia; Chelation Therapy; Child; Deferasirox; Deferoxamine; Female; Humans; Iron; Iron Chelating Agents; Iron Overload; Liver; Male; Myocardium; Prospective Studies; Transfusion Reaction; Treatment Outcome; Triazoles

2015
Deferasirox effect on renal haemodynamic parameters in patients with transfusion-dependent β thalassaemia.
    British journal of haematology, 2015, Volume: 168, Issue:6

    Topics: Adult; Benzoates; beta-Thalassemia; Biomarkers; Chelation Therapy; Creatinine; Deferasirox; Female; Ferritins; Glomerular Filtration Rate; Hemodynamics; Humans; Iron Chelating Agents; Iron Overload; Male; Middle Aged; Renal Circulation; Transfusion Reaction; Triazoles; Young Adult

2015
Effects of deferasirox-deferoxamine on myocardial and liver iron in patients with severe transfusional iron overload.
    Blood, 2015, Jun-18, Volume: 125, Issue:25

    Topics: Adolescent; Adult; Benzoates; Child; Deferasirox; Deferoxamine; Female; Heart; Humans; Iron Chelating Agents; Iron Overload; Liver; Male; Myocardium; Siderophores; Transfusion Reaction; Triazoles; Young Adult

2015
Liver iron concentration measurements by MRI in chronically transfused children with sickle cell anemia: baseline results from the TWiTCH trial.
    American journal of hematology, 2015, Volume: 90, Issue:9

    Topics: Adolescent; Anemia, Sickle Cell; Antisickling Agents; Benzoates; Biological Assay; Child; Child, Preschool; Deferasirox; Deferoxamine; Female; Humans; Hydroxyurea; Iron; Iron Chelating Agents; Iron Overload; Liver; Magnetic Resonance Imaging; Male; Stroke; Transfusion Reaction; Triazoles; Ultrasonography, Doppler, Transcranial

2015
CONIFER - Non-Interventional Study to Evaluate Therapy Monitoring During Deferasirox Treatment of Iron Toxicity in Myelodysplastic Syndrome Patients with Transfusional Iron Overload.
    Oncology research and treatment, 2016, Volume: 39, Issue:7-8

    Topics: Acute Kidney Injury; Adult; Aged; Aged, 80 and over; Benzoates; Deferasirox; Dose-Response Relationship, Drug; Drug Monitoring; Female; Gastrointestinal Diseases; Humans; Iron Chelating Agents; Iron Overload; Male; Middle Aged; Myelodysplastic Syndromes; Transfusion Reaction; Treatment Outcome; Triazoles

2016
Cardiac iron load and function in transfused patients treated with deferasirox (the MILE study).
    European journal of haematology, 2017, Volume: 98, Issue:2

    Topics: Adolescent; Adult; Aged; Benzoates; Blood Transfusion; Chelation Therapy; Deferasirox; Female; Ferritins; Heart Function Tests; Hemoglobinopathies; Humans; Iron; Iron Chelating Agents; Iron Overload; Magnetic Resonance Imaging; Male; Middle Aged; Myocardium; Transfusion Reaction; Treatment Outcome; Triazoles; Young Adult

2017
Limitations of serum ferritin to predict liver iron concentration responses to deferasirox therapy in patients with transfusion-dependent thalassaemia.
    European journal of haematology, 2017, Volume: 98, Issue:3

    Topics: Adolescent; Adult; Benzoates; Biomarkers; Chelation Therapy; Child; Child, Preschool; Deferasirox; Female; Ferritins; Humans; Iron; Iron Chelating Agents; Iron Overload; Liver; Male; Middle Aged; Prognosis; ROC Curve; Thalassemia; Transfusion Reaction; Treatment Outcome; Triazoles; Young Adult

2017
Deferasirox in MDS patients with transfusion-caused iron overload--a phase-II study.
    Annals of hematology, 2009, Volume: 88, Issue:4

    Topics: Aged; Aged, 80 and over; Benzoates; Bone Marrow; Deferasirox; Ferritins; Humans; Iron; Iron Overload; Liver; Magnetic Resonance Imaging; Middle Aged; Myelodysplastic Syndromes; Transfusion Reaction; Treatment Outcome; Triazoles

2009
Deferasirox pharmacokinetics in patients with adequate versus inadequate response.
    Blood, 2009, Nov-05, Volume: 114, Issue:19

    Topics: Adolescent; Adult; Anemia; Benzoates; Biological Availability; Child; Child, Preschool; Cohort Studies; Deferasirox; Female; Humans; Iron Chelating Agents; Iron Overload; Liver; Male; Pharmacogenetics; Prospective Studies; Transfusion Reaction; Triazoles; Young Adult

2009
Pharmacokinetics, metabolism, and disposition of deferasirox in beta-thalassemic patients with transfusion-dependent iron overload who are at pharmacokinetic steady state.
    Drug metabolism and disposition: the biological fate of chemicals, 2010, Volume: 38, Issue:5

    Topics: Adult; Animals; Area Under Curve; Arylsulfatases; Benzoates; beta-Thalassemia; Cells, Cultured; Deferasirox; Feces; Female; Glucuronidase; Glucuronides; Hepatocytes; Humans; Hydroxylation; Iron Chelating Agents; Iron Overload; Male; Molecular Structure; Rats; Spectrometry, Mass, Electrospray Ionization; Sulfuric Acid Esters; Transfusion Reaction; Triazoles; Young Adult

2010
Follow-up report on the 2-year cardiac data from a deferasirox monotherapy trial.
    American journal of hematology, 2010, Volume: 85, Issue:10

    Topics: Benzoates; beta-Thalassemia; Cardiomyopathies; Chelation Therapy; Deferasirox; Ferritins; Follow-Up Studies; Humans; Iron Chelating Agents; Liver Diseases; Siderosis; Stroke Volume; Transfusion Reaction; Treatment Outcome; Triazoles

2010
Long-term safety and efficacy of deferasirox (Exjade) for up to 5 years in transfusional iron-overloaded patients with sickle cell disease.
    British journal of haematology, 2011, Volume: 154, Issue:3

    Topics: Adolescent; Adult; Aged; Anemia, Sickle Cell; Benzoates; Child; Child, Preschool; Deferasirox; Drug Administration Schedule; Female; Gastrointestinal Diseases; Humans; Iron Chelating Agents; Iron Overload; Male; Middle Aged; Transfusion Reaction; Treatment Outcome; Triazoles; Young Adult

2011
[Curative effects and safety of deferasirox in treatment of iron overload in children with β-thalassemia major].
    Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics, 2011, Volume: 13, Issue:7

    Topics: Adolescent; Adult; Benzoates; beta-Thalassemia; Child; Child, Preschool; Deferasirox; Dose-Response Relationship, Drug; Female; Ferritins; Humans; Iron Chelating Agents; Iron Overload; Male; Transfusion Reaction; Triazoles

2011
Transfusional iron overload in children with sickle cell anemia on chronic transfusion therapy for secondary stroke prevention.
    American journal of hematology, 2012, Volume: 87, Issue:2

    Topics: Adolescent; Anemia, Sickle Cell; Benzoates; Chelation Therapy; Child; Deferasirox; Female; Ferritins; Humans; Iron; Iron Chelating Agents; Iron Overload; Liver; Male; Secondary Prevention; Stroke; Transfusion Reaction; Triazoles; Young Adult

2012
Hematologic responses to deferasirox therapy in transfusion-dependent patients with myelodysplastic syndromes.
    Haematologica, 2012, Volume: 97, Issue:9

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Benzoates; Blood Platelets; Child; Deferasirox; Female; Follow-Up Studies; Hemoglobins; Humans; Iron Chelating Agents; Iron Overload; Male; Middle Aged; Myelodysplastic Syndromes; Neoplasm Recurrence, Local; Neutrophils; Prognosis; Prospective Studies; Survival Rate; Transfusion Reaction; Triazoles; Young Adult

2012
Results from a 1-year, open-label, single arm, multi-center trial evaluating the efficacy and safety of oral Deferasirox in patients diagnosed with low and int-1 risk myelodysplastic syndrome (MDS) and transfusion-dependent iron overload.
    Annals of hematology, 2013, Volume: 92, Issue:2

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Benzoates; Chelation Therapy; Creatinine; Deferasirox; Drug Eruptions; Female; Ferritins; Gastrointestinal Diseases; Humans; Iron; Iron Chelating Agents; Iron Overload; Liver; Magnetic Resonance Imaging; Male; Middle Aged; Myelodysplastic Syndromes; Risk; Transfusion Reaction; Treatment Outcome; Triazoles

2013
Evaluation of ICL670, a once-daily oral iron chelator in a phase III clinical trial of beta-thalassemia patients with transfusional iron overload.
    Annals of the New York Academy of Sciences, 2005, Volume: 1054

    Topics: Administration, Oral; Adult; Benzoates; beta-Thalassemia; Chelation Therapy; Child; Deferasirox; Dose-Response Relationship, Drug; Hemosiderosis; Humans; Iron; Iron Chelating Agents; Iron Overload; Liver; Transfusion Reaction; Treatment Outcome; Triazoles

2005
Randomized phase II trial of deferasirox (Exjade, ICL670), a once-daily, orally-administered iron chelator, in comparison to deferoxamine in thalassemia patients with transfusional iron overload.
    Haematologica, 2006, Volume: 91, Issue:7

    Topics: Adolescent; Adult; Benzoates; beta-Thalassemia; Deferasirox; Deferoxamine; Female; Humans; Iron Chelating Agents; Iron Overload; Male; Middle Aged; Transfusion Reaction; Treatment Outcome; Triazoles

2006
Patient-reported outcomes of deferasirox (Exjade, ICL670) versus deferoxamine in sickle cell disease patients with transfusional hemosiderosis. Substudy of a randomized open-label phase II trial.
    Acta haematologica, 2008, Volume: 119, Issue:3

    Topics: Absenteeism; Adolescent; Adult; Anemia, Sickle Cell; Benzoates; Chelation Therapy; Child; Child, Preschool; Deferasirox; Deferoxamine; Female; Hemosiderosis; Humans; Iron; Iron Chelating Agents; Male; Middle Aged; Patient Satisfaction; Surveys and Questionnaires; Transfusion Reaction; Treatment Outcome; Triazoles

2008

Other Studies

59 other study(ies) available for deferasirox and Transfusion Reaction

ArticleYear
Reduction of Liver Iron Load in Adult Patients with β-Thalassemia Major Treated with Modern Chelation Modalities.
    Folia medica, 2020, Jun-30, Volume: 62, Issue:2

    Topics: Adult; beta-Thalassemia; Blood Transfusion; Deferasirox; Deferiprone; Deferoxamine; Female; Ferritins; Humans; Iron Overload; Liver; Magnetic Resonance Imaging; Male; Transfusion Reaction; Treatment Outcome; Young Adult

2020
Heavy metal.
    Blood, 2020, 10-22, Volume: 136, Issue:17

    Topics: Aged, 80 and over; Anemia, Sideroblastic; Arteriosclerosis; Biopsy; Blood Transfusion; Blood Vessels; Bone Marrow; Deferasirox; Female; Humans; Iron; Iron Overload; Metals, Heavy; Myelodysplastic-Myeloproliferative Diseases; Thrombocytosis; Transfusion Reaction; Treatment Failure

2020
Iron chelating properties of Eltrombopag: Investigating its role in thalassemia-induced osteoporosis.
    PloS one, 2018, Volume: 13, Issue:12

    Topics: Adult; Benzoates; Blood Transfusion; Bone and Bones; Cell Differentiation; Deferasirox; Drug Evaluation; Female; Ferritins; Healthy Volunteers; Humans; Hydrazines; Iron; Iron Chelating Agents; Iron Overload; Leukocytes, Mononuclear; Osteoclasts; Osteoporosis; Primary Cell Culture; Pyrazoles; Receptors, Thrombopoietin; Thalassemia; Transfusion Reaction

2018
Single-center retrospective study of the effectiveness and toxicity of the oral iron chelating drugs deferiprone and deferasirox.
    PloS one, 2019, Volume: 14, Issue:2

    Topics: Administration, Oral; Anemia, Diamond-Blackfan; beta-Thalassemia; Blood Transfusion; Deferasirox; Deferiprone; Electronic Health Records; Female; Humans; Iron Chelating Agents; Iron Overload; Male; Retrospective Studies; Transfusion Reaction

2019
Clinical characteristics and management of iron overload in 631 patients with chronic transfusion dependency: results from a multicentre, observational study.
    Blood transfusion = Trasfusione del sangue, 2014, Volume: 12 Suppl 1

    Topics: Aged; Benzoates; Chelation Therapy; Comorbidity; Deferasirox; Disease Management; Erythrocyte Transfusion; Female; Ferritins; Guideline Adherence; Hematologic Diseases; Humans; Iron; Iron Chelating Agents; Iron Overload; Male; Middle Aged; Practice Guidelines as Topic; Spain; Transfusion Reaction; Triazoles

2014
A pharmaco-economic evaluation of deferasirox for treating patients with iron overload caused by transfusion-dependent thalassemia in Taiwan.
    Journal of the Formosan Medical Association = Taiwan yi zhi, 2013, Volume: 112, Issue:4

    Topics: Benzoates; Child, Preschool; Deferasirox; Deferoxamine; Health Care Costs; Humans; Iron Chelating Agents; Iron Overload; Markov Chains; Quality-Adjusted Life Years; Thalassemia; Transfusion Reaction; Triazoles

2013
Twice daily deferasirox significantly improves clinical efficacy in transfusion dependent thalassaemias who were inadequate responders to standard once daily dose.
    Blood cells, molecules & diseases, 2013, Volume: 51, Issue:2

    Topics: Benzoates; Deferasirox; Humans; Iron Chelating Agents; Iron Overload; Thalassemia; Transfusion Reaction; Treatment Outcome; Triazoles

2013
Nephrolithiasis in patients exposed to deferasirox and desferioxamine: probably an age-linked event with different effects on some renal parameters.
    Annals of hematology, 2014, Volume: 93, Issue:3

    Topics: Adult; Aging; Benzoates; beta-Thalassemia; Chelation Therapy; Deferasirox; Deferoxamine; Disease Susceptibility; Female; Glomerular Filtration Rate; Humans; Hyperuricemia; Incidence; Iron Chelating Agents; Iron Overload; Italy; Kidney; Male; Nephrolithiasis; Retrospective Studies; Transfusion Reaction; Triazoles; Ultrasonography

2014
A comparative study of deferasirox and deferiprone in the treatment of iron overload in patients with myelodysplastic syndromes.
    Leukemia research, 2013, Volume: 37, Issue:12

    Topics: Adult; Aged; Aged, 80 and over; Benzoates; Chelation Therapy; Deferasirox; Deferiprone; Female; Ferritins; Humans; Iron Chelating Agents; Iron Overload; Male; Middle Aged; Myelodysplastic Syndromes; Pyridones; Transfusion Reaction; Triazoles

2013
Impact of heart magnetic resonance imaging on chelation choices, compliance with treatment and risk of heart disease in patients with thalassaemia major.
    British journal of haematology, 2013, Volume: 163, Issue:3

    Topics: Adult; Area Under Curve; Arrhythmias, Cardiac; Benzoates; beta-Thalassemia; Chelation Therapy; Deferasirox; Deferiprone; Deferoxamine; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Heart Failure; Humans; Iron; Iron Chelating Agents; Iron Overload; Magnetic Resonance Imaging; Male; Myocardium; Patient Compliance; Predictive Value of Tests; Pyridones; Risk; ROC Curve; Sampling Studies; Transfusion Reaction; Triazoles; Young Adult

2013
Iron chelators in myelodysplastic syndrome: to lower ferritin levels or to improve survival?
    Leukemia research, 2013, Volume: 37, Issue:12

    Topics: Benzoates; Deferasirox; Deferiprone; Female; Humans; Iron Chelating Agents; Iron Overload; Male; Myelodysplastic Syndromes; Pyridones; Transfusion Reaction; Triazoles

2013
Korean guideline for iron chelation therapy in transfusion-induced iron overload.
    Journal of Korean medical science, 2013, Volume: 28, Issue:11

    Topics: Anemia, Aplastic; Benzoates; Chelation Therapy; Deferasirox; Deferiprone; Humans; Iron Chelating Agents; Iron Overload; Myelodysplastic Syndromes; Pyridones; Republic of Korea; Transfusion Reaction; Triazoles

2013
[Hematologic improvement with deferasirox following tandem antithymocyte globulin treatment in a transfusion-dependent patient with severe aplastic anemia].
    [Rinsho ketsueki] The Japanese journal of clinical hematology, 2013, Volume: 54, Issue:11

    Topics: Anemia, Aplastic; Antilymphocyte Serum; Benzoates; Blood Transfusion; Cyclosporine; Deferasirox; Humans; Iron Chelating Agents; Male; Middle Aged; Transfusion Reaction; Treatment Outcome; Triazoles

2013
[The role of iron metabolism in myelodysplastic syndromes].
    Recenti progressi in medicina, 2014, Volume: 105, Issue:3

    Topics: Anemia; Benzoates; Blood Transfusion; Chelation Therapy; Deferasirox; Ferritins; Hematopoietic Stem Cell Transplantation; Humans; Iron; Iron Chelating Agents; Iron Overload; Myelodysplastic Syndromes; Risk; Transfusion Reaction; Triazoles

2014
Biopsy-based calibration of T2* magnetic resonance for estimation of liver iron concentration and comparison with R2 Ferriscan.
    Journal of cardiovascular magnetic resonance : official journal of the Society for Cardiovascular Magnetic Resonance, 2014, Jun-10, Volume: 16

    Topics: Algorithms; Benzoates; Biomarkers; Biopsy; Calibration; Deferasirox; Hemosiderosis; Humans; Image Interpretation, Computer-Assisted; Iron; Iron Chelating Agents; Least-Squares Analysis; Linear Models; Liver; Magnetic Resonance Imaging; Observer Variation; Predictive Value of Tests; Reproducibility of Results; Retrospective Studies; Transfusion Reaction; Triazoles

2014
Elevated total iron-binding capacity as a predictor of response to deferasirox therapy in the setting of chronic iron overload.
    International journal of hematology, 2014, Volume: 100, Issue:3

    Topics: Benzoates; Blood Proteins; Deferasirox; Drug Monitoring; Female; Ferritins; Hematologic Neoplasms; Humans; Iron; Iron Chelating Agents; Iron Overload; Male; Middle Aged; Multivariate Analysis; Prognosis; Protein Binding; Retrospective Studies; ROC Curve; Transfusion Reaction; Treatment Outcome; Triazoles

2014
Incidence of deferasirox-associated renal tubular dysfunction in children and young adults with beta-thalassaemia.
    British journal of haematology, 2014, Volume: 167, Issue:3

    Topics: Adolescent; Alkalosis; Benzoates; beta 2-Microglobulin; beta-Thalassemia; Chelation Therapy; Child; Child, Preschool; Deferasirox; Deferiprone; Deferoxamine; Fanconi Syndrome; Female; Humans; Iron Chelating Agents; Kidney Diseases; Kidney Tubules; Male; Pyridones; Retrospective Studies; Transfusion Reaction; Triazoles; Water-Electrolyte Imbalance; Young Adult

2014
Incidence of ototoxicity in pediatric patients with transfusion-dependent thalassemia who are less well-chelated by mono- and combined therapy of iron chelating agents.
    Hemoglobin, 2014, Volume: 38, Issue:5

    Topics: Adolescent; Adult; Benzoates; Chelation Therapy; Child; Child, Preschool; Deferasirox; Deferiprone; Deferoxamine; Developing Countries; Drug Monitoring; Drug Therapy, Combination; Female; Follow-Up Studies; Hearing Loss, Sensorineural; Humans; Incidence; Iron Chelating Agents; Iron Overload; Male; Pyridones; Retrospective Studies; Thailand; Thalassemia; Transfusion Reaction; Triazoles; Young Adult

2014
Deferasirox for iron chelation in multitransfused children with sickle cell disease; long-term experience in the East London clinical haemoglobinopathy network.
    European journal of haematology, 2015, Volume: 94, Issue:4

    Topics: Adolescent; Alanine Transaminase; Anemia, Sickle Cell; Benzoates; Child; Child, Preschool; Deferasirox; Female; Ferritins; Humans; Iron Chelating Agents; Iron Overload; Kidney Function Tests; Liver; London; Male; Medication Adherence; Retrospective Studies; Time Factors; Transfusion Reaction; Treatment Outcome; Triazoles

2015
Long-term effects of an oral iron chelator, deferasirox, in hemodialysis patients with iron overload.
    Hematology (Amsterdam, Netherlands), 2015, Volume: 20, Issue:5

    Topics: Administration, Oral; Adult; Aged; Anemia; Benzoates; Chelation Therapy; Deferasirox; Female; Hematopoiesis; Humans; Iron; Iron Chelating Agents; Iron Overload; Male; Middle Aged; Renal Dialysis; Renal Insufficiency, Chronic; Retrospective Studies; Transfusion Reaction; Treatment Outcome; Triazoles

2015
Health-related quality of life in transfusion-dependent patients with myelodysplastic syndromes: a prospective study to assess the impact of iron chelation therapy.
    BMJ supportive & palliative care, 2016, Volume: 6, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Benzoates; Deferasirox; Female; Humans; Iron Chelating Agents; Male; Middle Aged; Myelodysplastic Syndromes; Prospective Studies; Quality of Life; Transfusion Reaction; Treatment Outcome; Triazoles; Young Adult

2016
Deferasirox chelation therapy in patients with transfusion-dependent MDS: a 'real-world' report from two regional Italian registries: Gruppo Romano Mielodisplasie and Registro Basilicata.
    European journal of haematology, 2015, Volume: 95, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Benzoates; Deferasirox; Female; Ferritins; Hematopoiesis; Humans; Iron; Iron Chelating Agents; Iron Overload; Italy; Male; Middle Aged; Myelodysplastic Syndromes; Registries; Retrospective Studies; Transfusion Reaction; Treatment Outcome; Triazoles

2015
The deferiprone and deferasirox combination is efficacious in iron overloaded patients with β-thalassemia major: A prospective, single center, open-label study.
    Pediatric blood & cancer, 2015, Volume: 62, Issue:9

    Topics: Adolescent; Adult; Benzoates; beta-Thalassemia; Chelation Therapy; Chemical and Drug Induced Liver Injury; Child; Child, Preschool; Deferasirox; Deferiprone; Drug Eruptions; Drug Therapy, Combination; Female; Ferritins; Gastrointestinal Diseases; Humans; Iron; Iron Chelating Agents; Iron Overload; Joint Diseases; Male; Prospective Studies; Proteinuria; Pyridones; Transfusion Reaction; Treatment Outcome; Triazoles; Young Adult

2015
GFR in Patients with β-Thalassemia Major.
    Clinical journal of the American Society of Nephrology : CJASN, 2015, Aug-07, Volume: 10, Issue:8

    Topics: Adult; Benzoates; beta-Thalassemia; Biomarkers; Creatinine; Deferasirox; Female; Glomerular Filtration Rate; Humans; Inulin; Iron Chelating Agents; Israel; Kidney; Kidney Diseases; Male; Models, Biological; Outpatient Clinics, Hospital; Predictive Value of Tests; Reproducibility of Results; Transfusion Reaction; Triazoles; Young Adult

2015
Chelation efficacy and erythroid response during deferasirox treatment in patients with myeloproliferative neoplasms in fibrotic phase.
    European journal of haematology, 2016, Volume: 96, Issue:6

    Topics: Aged; Benzoates; Chelation Therapy; Deferasirox; Erythrocyte Indices; Erythropoiesis; Female; Fibrosis; Follow-Up Studies; Humans; Iron Chelating Agents; Iron Overload; Male; Middle Aged; Myeloproliferative Disorders; Retrospective Studies; Transfusion Reaction; Treatment Outcome; Triazoles

2016
Effect of deferasirox on iron overload in patients with transfusion-dependent haemoglobinopathies.
    Blood cells, molecules & diseases, 2015, Volume: 55, Issue:4

    Topics: Adolescent; Adult; Benzoates; Child; Deferasirox; Female; Ferritins; Hemoglobinopathies; Humans; Iron; Iron Chelating Agents; Iron Overload; Liver; Male; Middle Aged; Myocardium; Retrospective Studies; Stroke Volume; Transfusion Reaction; Treatment Outcome; Triazoles; Ventricular Function, Left; Young Adult

2015
Impact of medication adherence on the effectiveness of deferasirox for the treatment of transfusional iron overload in myelodysplastic syndrome.
    Journal of clinical pharmacy and therapeutics, 2016, Volume: 41, Issue:1

    Topics: Aged; Benzoates; Blood Transfusion; Deferasirox; Female; Ferritins; Follow-Up Studies; Hospitals, University; Humans; Iron Chelating Agents; Iron Overload; Longitudinal Studies; Male; Medication Adherence; Middle Aged; Myelodysplastic Syndromes; Retrospective Studies; Transfusion Reaction; Treatment Outcome; Triazoles

2016
Deferasirox and children: From clinical trials to the real world.
    American journal of hematology, 2016, Volume: 91, Issue:6

    Topics: Age Factors; Benzoates; beta-Thalassemia; Child; Clinical Trials as Topic; Deferasirox; Humans; Iron Chelating Agents; Iron Overload; Transfusion Reaction; Treatment Outcome; Triazoles

2016
Longitudinal changes of endocrine and bone disease in adults with β-thalassemia major receiving different iron chelators over 5 years.
    Annals of hematology, 2016, Volume: 95, Issue:5

    Topics: Adult; Benzoates; beta-Thalassemia; Chelation Therapy; Deferasirox; Deferiprone; Deferoxamine; Diabetes Mellitus; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Hypogonadism; Hypothyroidism; Iron Chelating Agents; Iron Overload; Male; Middle Aged; Osteoporosis; Prevalence; Pyridones; Retrospective Studies; Transfusion Reaction; Triazoles

2016
Comparative Efficacy and Safety of Oral Iron Chelators and their Novel Combination in Children with Thalassemia.
    Indian pediatrics, 2016, Volume: 53, Issue:3

    Topics: Adolescent; Benzoates; Child; Child, Preschool; Deferasirox; Deferiprone; Drug Therapy, Combination; Ferritins; Humans; Iron Chelating Agents; Iron Overload; Prospective Studies; Pyridones; Thalassemia; Transfusion Reaction; Triazoles

2016
Evaluation of Proteinuria in β-Thalassemia Major Patients With and Without Diabetes Mellitus Taking Deferasirox.
    Journal of pediatric hematology/oncology, 2017, Volume: 39, Issue:1

    Topics: Adolescent; Adult; Benzoates; beta-Thalassemia; Creatinine; Cross-Sectional Studies; Deferasirox; Deferiprone; Diabetes Mellitus; Dose-Response Relationship, Drug; Female; Humans; Iron Chelating Agents; Iron Overload; Male; Proteinuria; Pyridones; Transfusion Reaction; Triazoles; Young Adult

2017
Multidisciplinary evaluation at baseline and during treatment improves the rate of compliance and efficacy of deferasirox in elderly myelodysplastic patients.
    International journal of clinical oncology, 2017, Volume: 22, Issue:2

    Topics: Aged; Aged, 80 and over; Benzoates; Deferasirox; Female; Humans; Iron Chelating Agents; Iron Overload; Male; Middle Aged; Myelodysplastic Syndromes; Retrospective Studies; Transfusion Reaction; Treatment Outcome; Triazoles

2017
Long-term safety and efficacy of deferasirox in young pediatric patients with transfusional hemosiderosis: Results from a 5-year observational study (ENTRUST).
    Pediatric blood & cancer, 2017, Volume: 64, Issue:9

    Topics: Benzoates; Chelation Therapy; Child, Preschool; Deferasirox; Female; Hematologic Diseases; Hemosiderosis; Humans; Iron Chelating Agents; Male; Transfusion Reaction; Triazoles

2017
Hypocalcemia in a dialysis patient treated with deferasirox for iron overload.
    American journal of kidney diseases : the official journal of the National Kidney Foundation, 2008, Volume: 52, Issue:3

    Topics: Adult; Anemia, Sickle Cell; Benzoates; Deferasirox; Erythropoietin; Female; Humans; Hypertension; Hypocalcemia; Iron Chelating Agents; Iron Overload; Kidney Failure, Chronic; Peritoneal Dialysis; Transfusion Reaction; Triazoles

2008
Update on toxicity and efficacy aspects of treatment with deferasirox and its implication on the morbidity and mortality of transfused iron loaded patients.
    Expert opinion on drug safety, 2008, Volume: 7, Issue:6

    Topics: Benzoates; Deferasirox; Deferiprone; Drug Therapy, Combination; Heart; Humans; Iron Chelating Agents; Iron Overload; Pyridones; Transfusion Reaction; Triazoles

2008
Transparency and access to full information for the fatal or serious toxicity risks, low efficacy and high price of deferasirox, could increase the prospect of improved iron chelation therapy worldwide.
    Hemoglobin, 2008, Volume: 32, Issue:6

    Topics: Acute Kidney Injury; Benzoates; Chelation Therapy; Cost-Benefit Analysis; Deferasirox; Deferiprone; Deferoxamine; Drug Costs; Drug Industry; Humans; Iron Chelating Agents; Iron Overload; Pyridones; Transfusion Reaction; Triazoles; Truth Disclosure

2008
Iron chelation therapy in myelodysplastic syndrome - Cui bono?
    Leukemia, 2009, Volume: 23, Issue:8

    Topics: Aged; Benzoates; Biomarkers; Chelation Therapy; Deferasirox; Ferritins; Humans; Iron; Iron Chelating Agents; Iron Overload; Life Expectancy; Middle Aged; Myelodysplastic Syndromes; Transfusion Reaction; Triazoles

2009
Deferasirox treatment may be associated with reversible renal Fanconi syndrome.
    American journal of hematology, 2010, Volume: 85, Issue:2

    Topics: Adolescent; Benzoates; Child; Deferasirox; Fanconi Syndrome; Female; Humans; Iron Chelating Agents; Iron Overload; Kidney; Male; Transfusion Reaction; Triazoles

2010
Effect of iron chelator deferasirox on chronic anemia and thrombocytopenia in a transfusion-dependent patient with myelodysplastic syndrome.
    International journal of hematology, 2010, Volume: 91, Issue:2

    Topics: Aged; Anemia; Benzoates; Chronic Disease; Deferasirox; Female; Humans; Iron Chelating Agents; Iron Overload; Myelodysplastic Syndromes; Radiography; Thrombocytopenia; Transfusion Reaction; Triazoles

2010
Daily alternating deferasirox and deferiprone therapy for "hard-to-chelate" beta-thalassemia major patients.
    American journal of hematology, 2010, Volume: 85, Issue:6

    Topics: Administration, Oral; Arthralgia; Benzoates; beta-Thalassemia; Chelation Therapy; Deferasirox; Deferiprone; Deferoxamine; Drug Administration Schedule; Drug Eruptions; Drug Therapy, Combination; Female; Humans; Infusions, Subcutaneous; Iron Chelating Agents; Iron Overload; Pyridones; Transfusion Reaction; Triazoles; Young Adult

2010
Relation of chelation regimes to cardiac mortality and morbidity in patients with thalassaemia major: an observational study from a large Greek Unit.
    European journal of haematology, 2010, Volume: 85, Issue:4

    Topics: Adolescent; Adult; Age Factors; Benzoates; beta-Thalassemia; Child; Death; Deferasirox; Deferiprone; Deferoxamine; Female; Greece; Heart Diseases; Humans; Iron; Iron Chelating Agents; Iron Overload; Magnetic Resonance Spectroscopy; Male; Pyridones; Transfusion Reaction; Treatment Outcome; Triazoles; Young Adult

2010
Pathogenesis and management of iron toxicity in thalassemia.
    Annals of the New York Academy of Sciences, 2010, Volume: 1202

    Topics: Benzoates; Deferasirox; Deferiprone; Deferoxamine; Homeostasis; Humans; Iron; Iron Chelating Agents; Iron Overload; Models, Molecular; Pyridones; Reactive Oxygen Species; Thalassemia; Transferrin; Transfusion Reaction; Triazoles

2010
Restoration of hematopoiesis after iron chelation therapy with deferasirox in 2 children with severe aplastic anemia.
    Journal of pediatric hematology/oncology, 2010, Volume: 32, Issue:8

    Topics: Anemia, Aplastic; Benzoates; Child; Deferasirox; Hematopoiesis; Humans; Iron Chelating Agents; Iron Overload; Male; Severity of Illness Index; Transfusion Reaction; Triazoles

2010
Improved efficacy and tolerability of oral deferasirox by twice-daily dosing for patients with transfusion-dependent β-thalassemia.
    Pediatric blood & cancer, 2011, Volume: 56, Issue:3

    Topics: Administration, Oral; Adolescent; Adult; Benzoates; beta-Thalassemia; Child; Deferasirox; Drug Administration Schedule; Female; Ferritins; Humans; Iron Chelating Agents; Iron Overload; Male; Maximum Tolerated Dose; Retrospective Studies; Transfusion Reaction; Treatment Outcome; Triazoles; Young Adult

2011
Fanconi syndrome in a patient with β-thalassemia major after using deferasirox for 27 months.
    Transfusion, 2011, Volume: 51, Issue:5

    Topics: Adolescent; Benzoates; beta-Thalassemia; Deferasirox; Fanconi Syndrome; Hospitalization; Humans; Iron Chelating Agents; Iron Overload; Kidney; Male; Transfusion Reaction; Triazoles

2011
Safety and efficacy of deferasirox in multitransfused Indian children with β-thalassaemia major.
    Annals of tropical paediatrics, 2011, Volume: 31, Issue:1

    Topics: Adolescent; Benzoates; beta-Thalassemia; Child; Child, Preschool; Cross-Sectional Studies; Deferasirox; Female; Humans; India; Iron Chelating Agents; Iron Overload; Male; Transfusion Reaction; Triazoles

2011
Deferasirox treatment of iron-overloaded chelation-naïve and prechelated patients with myelodysplastic syndromes in medical practice: results from the observational studies eXtend and eXjange.
    European journal of haematology, 2012, Volume: 88, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Benzoates; Deferasirox; Female; Ferritins; Humans; Iron Chelating Agents; Iron Overload; Male; Middle Aged; Myelodysplastic Syndromes; Prospective Studies; Transfusion Reaction; Triazoles

2012
Iron overload during follow-up after tandem high-dose chemotherapy and autologous stem cell transplantation in patients with high-risk neuroblastoma.
    Journal of Korean medical science, 2012, Volume: 27, Issue:4

    Topics: Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Benzoates; Child; Child, Preschool; Creatinine; Deferasirox; Ferritins; Follow-Up Studies; Humans; Infant; Iron Chelating Agents; Iron Overload; Neuroblastoma; Retrospective Studies; Risk Factors; Stem Cell Transplantation; Transfusion Reaction; Transplantation, Autologous; Triazoles

2012
Deferasirox-induced renal impairment in children: an increasing concern for pediatricians.
    Pediatric nephrology (Berlin, Germany), 2012, Volume: 27, Issue:11

    Topics: Administration, Oral; Adolescent; Age Factors; Benzoates; Child; Deferasirox; Female; Glomerular Filtration Rate; Humans; Inulin; Iron Chelating Agents; Iron Overload; Kidney Diseases; Kidney Glomerulus; Kidney Tubules, Proximal; Male; Prospective Studies; Time Factors; Transfusion Reaction; Triazoles

2012
First report of drug-induced esophagitis by deferasirox.
    International journal of hematology, 2012, Volume: 95, Issue:6

    Topics: Benzoates; Deferasirox; Esophagitis; Humans; Iron Chelating Agents; Iron Overload; Male; Myelodysplastic Syndromes; Transfusion Reaction; Triazoles

2012
How I treat transfusional iron overload.
    Blood, 2012, Nov-01, Volume: 120, Issue:18

    Topics: Benzoates; Deferasirox; Deferiprone; Deferoxamine; Hematologic Diseases; Humans; Iron Chelating Agents; Iron Overload; Pyridones; Transfusion Reaction; Triazoles

2012
Nephrolithiasis in beta thalassemia major patients treated with deferasirox: an advent or an adverse event? A single Greek center experience.
    Annals of hematology, 2013, Volume: 92, Issue:2

    Topics: Adult; Benzoates; beta-Thalassemia; Chelation Therapy; Child; Child, Preschool; Deferasirox; Deferiprone; Female; Greece; Humans; Hypercalciuria; Hyperuricemia; Iron Chelating Agents; Iron Overload; Male; Nephrolithiasis; Postoperative Complications; Pyridones; Splenectomy; Transfusion Reaction; Triazoles; Young Adult

2013
Efficacy and safety of deferasirox at low and high iron burdens: results from the EPIC magnetic resonance imaging substudy.
    Annals of hematology, 2013, Volume: 92, Issue:2

    Topics: Adolescent; Adult; Benzoates; Chelation Therapy; Child; Child, Preschool; Cholelithiasis; Clinical Trials, Phase III as Topic; Creatinine; Deferasirox; Edema; Ethnicity; Female; Ferritins; Gastrointestinal Diseases; Hematologic Diseases; Hepatitis, Viral, Human; Humans; Infant; Iron; Iron Chelating Agents; Iron Overload; Kidney Diseases; Liver; Magnetic Resonance Imaging; Male; Multicenter Studies as Topic; Prospective Studies; Thalassemia; Transfusion Reaction; Triazoles; Young Adult

2013
[Transfusion reaction and HLA antibodies].
    Nihon rinsho. Japanese journal of clinical medicine, 2012, Volume: 70 Suppl 2

    Topics: Acute Lung Injury; Antibody Formation; Benzoates; Blood Transfusion; Deferasirox; Hematologic Neoplasms; Hemochromatosis; HLA Antigens; Humans; Iron Chelating Agents; Isoantibodies; Myelodysplastic Syndromes; Transfusion Reaction; Triazoles

2012
Improvement in hematopoiesis after iron chelation therapy with deferasirox in patients with aplastic anemia.
    Acta haematologica, 2013, Volume: 129, Issue:2

    Topics: Adult; Anemia, Aplastic; Benzoates; Chelation Therapy; Deferasirox; Erythrocyte Transfusion; Female; Ferritins; Hematopoiesis; Humans; Immunosuppressive Agents; Iron; Iron Chelating Agents; Iron Overload; Male; Platelet Transfusion; Transfusion Reaction; Triazoles

2013
Iranian experience of deferasirox (Exjade(®)) in transfusion-dependent patients with iron overload: what is the most effective dose based on serum ferritin levels?
    Hematology (Amsterdam, Netherlands), 2012, Volume: 17, Issue:6

    Topics: Adolescent; Adult; Benzoates; Child; Child, Preschool; Deferasirox; Female; Ferritins; Humans; Iron Chelating Agents; Iron Overload; Male; Retrospective Studies; Transfusion Reaction; Treatment Outcome; Triazoles; Young Adult

2012
Cost-utility analysis of oral deferasirox versus infusional deferoxamine in transfusion-dependent β-thalassemia patients.
    Transfusion, 2013, Volume: 53, Issue:8

    Topics: Administration, Oral; Adult; Benzoates; beta-Thalassemia; Cost-Benefit Analysis; Cross-Sectional Studies; Deferasirox; Deferoxamine; Drug Costs; Female; Humans; Infusions, Intravenous; Iran; Iron Chelating Agents; Iron Overload; Male; Markov Chains; Models, Economic; Quality-Adjusted Life Years; Transfusion Reaction; Treatment Outcome; Triazoles

2013
Molecule of the month. Deferasirox.
    Drug news & perspectives, 2005, Volume: 18, Issue:7

    Topics: Benzoates; Chelating Agents; Deferasirox; Humans; Iron Overload; Multicenter Studies as Topic; Transfusion Reaction; Triazoles

2005
ICL670A: a new synthetic oral chelator: evaluation in hypertransfused rats with selective radioiron probes of hepatocellular and reticuloendothelial iron stores and in iron-loaded rat heart cells in culture.
    Blood, 2001, Feb-15, Volume: 97, Issue:4

    Topics: Animals; Benzoates; Bile; Cells, Cultured; Deferasirox; Deferoxamine; Drug Evaluation, Preclinical; Erythrocyte Transfusion; Erythrocytes, Abnormal; Feces; Female; Ferritins; Heart; Hepatocytes; Hot Temperature; Injections, Intravenous; Iron Chelating Agents; Iron Overload; Iron Radioisotopes; Liver; Mice; Molecular Structure; Mononuclear Phagocyte System; Myocardium; Organ Specificity; Rats; Rats, Wistar; Tissue Distribution; Transfusion Reaction; Triazoles; Urine

2001